Intra-Cellular Therapies, Inc.
ITCI
주식 순위
#1693
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
주가
$131.87
마지막 동기화: 2025-04-02
시가총액
$12.68B
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 Intra-Cellular Therapies, Inc. (ITCI)
카테고리
Healthcare
Intra-Cellular Therapies, Inc. (ITCI)의 EPS
December 2024 기준 EPS TTM: $-0.01
Intra-Cellular Therapies, Inc.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 $-0.01입니다. 2023년 말에는 회사의 EPS가 $-1.46였으며, 이는 2022년의 EPS $-2.72와 감소입니다.
Intra-Cellular Therapies, Inc.의 EPS 기록 (2013 ~ 2026)
매년 말의 EPS
| 연도 | EPS | 변화 |
|---|---|---|
| 2026 (TTM) | $-0.01 | -98.61% |
| 2024 | $-0.72 | -50.68% |
| 2023 | $-1.46 | -46.32% |
| 2022 | $-2.72 | -22.29% |
| 2021 | $-3.50 | 8.36% |
| 2020 | $-3.23 | 20.52% |
| 2019 | $-2.68 | -5.63% |
| 2018 | $-2.84 | 33.96% |
| 2017 | $-2.12 | -21.19% |
| 2016 | $-2.69 | -7.56% |
| 2015 | $-2.91 | 171.96% |
| 2014 | $-1.07 | -31.41% |
| 2013 | $-1.56 | 0.00% |
유사 기업 또는 경쟁사의 EPS
| 회사 | EPS | EPS 차이 | 국가 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $0.56 | -5,663.00% |
IN
|
